China SXT Pharmaceuticals announced on March 23, 2026 that it has completed a share re‑classification that will take effect at the market opening on March 24, 2026. The re‑classification creates a dual‑class structure in which the company’s existing ordinary shares are re‑designated as Class A Ordinary Shares with no voting rights, while a new Class B Ordinary Share is issued that grants holders fifty (50) votes per share on any shareholder resolution.
The change was effected by filing the amended and restated Memorandum and Articles of Association with the British Virgin Islands registry. All shares held through banks, brokers or other nominees will be automatically adjusted to reflect the new share classes, and Class A shares will trade under the symbol “SXTC.”
This corporate action follows a 1‑for‑150 share consolidation that became effective on February 3, 2026, which reduced the outstanding share count from roughly 143.7 million to about 958,000. The company also raised $10 million through a registered direct offering on January 9, 2026, indicating an active effort to manage its capital structure amid a significant decline in its stock price and a market capitalization of only $1.31 million.
China’s regulatory environment has evolved to allow “innovative enterprises” to issue shares with multiple voting rights. The dual‑class structure adopted by China SXT Pharmaceuticals aligns with these new rules and reflects a strategic decision to preserve founder control while still raising capital. By concentrating voting power in Class B shares, the company can issue additional shares without diluting the control of its founding shareholders, thereby protecting against hostile takeovers and maintaining a long‑term strategic vision.
The re‑classification has clear governance implications. It concentrates voting authority, which can provide stability but also raises concerns about accountability to minority shareholders. The move also positions the company to issue more shares in the future without compromising control, potentially easing future capital‑raising efforts. Investors will need to weigh the benefits of founder control against the risks of reduced shareholder influence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.